The quiet revolution reshaping drug development
Episode 18 continues the BIO deep dive with Chandima Bandara of Precision Quantomics, tackling one of biotech’s biggest truths: most drugs fail—not because the ideas are bad, but because the data is incomplete.
The conversation explores why LC-MS/MS and quantitative proteomics might be the missing layer, how small companies are leapfrogging Big Pharma, and how Bullpen’s Money Ball is rewriting the blueprint for scientific storytelling. This is science + strategy + startup reality, all in one.
Topics:
🙏 Special thanks to Bullpen for championing founders and creating spaces like “Money Ball” where community meets real traction.
